drugset / Trial / NCT02632903

Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study

NCT02632903

NaSingle-groupOpen-labelTreatment

Summary

This study explores the effect of zoledronic acid on incident vertebral fractures and osteonecrotic lesions in children recently diagnosed with acute lymphoblastic leukemia.

Timeline

Start
2016-10
Primary completion
2018-03
Completion
2018-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 0.025 mg/kg